---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-001760"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T03:49:48.591134+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arbutus reports FY2024 net loss $69.9M; cuts workforce 57%, appoints new CFO

## Summary
- Net loss for 2024 was $69.9M ($0.38/share) vs $72.8M ($0.44) in 2023; revenue $6.2M down from $18.1M.
- Cash and marketable securities $122.6M at Dec 31, 2024; ATM program terminated.
- Workforce reduced by 57% in Q1 2025, retaining 19 employees; expects $11-13M restructuring charge.
- Tuan Nguyen appointed CFO effective March 28, 2025, replacing David Hastings; General Counsel and CMO departures.
- Moderna U.S. LNP patent trial scheduled for Sept 2025; Pfizer/BioNTech claim construction ruling pending; international lawsuits filed March 2025.

## SEC filing metadata
- accession: 0001171843-25-001760
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184325001760/0001171843-25-001760-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184325001760/f8k_032725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-001760
- JSON: https://secwatch.observer/filing/0001171843-25-001760.json
- Plain text: https://secwatch.observer/filing/0001171843-25-001760.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.